Skip to main content
. Author manuscript; available in PMC: 2015 Feb 23.
Published in final edited form as: Lancet. 2004 Jul-Aug;364(9432):438–447. doi: 10.1016/S0140-6736(04)16767-6

Table 5. Temporal trends of the efficacy of mefloquine monotherapy and parasite genotype in primary infections.

1990 1991 1992 1993 1994*
Day 28 failure rate (complete cohort) 3/63 (5%) 41/314 (13%) 56/231 (24%) 65/180 (36%) 27/73 (37%)
Day 7 failure rate (complete cohort) 0/79 (0%) 12/363 (3%) 19/273 (7%) 30/194 (16%) 10/77 (13%)
Isolates with 1 copy of pfmdr1 32/42 (76%) 17/60 (72%) 28/51 (55%) 4/11 (36%) NA
Isolates with 2 copies of pfmdr1 6/42 (14%) 8/60 (13%) 14/51 (28%) 5/11 (45%) NA
Isolates with ≥3 copies of pfmdr1 4/42 (10%) 9/60 (15%) 9/51 (18%) 2/11 (18%) NA
N86Y 3/38 (8%) 4/60 (7%) 1/48 (2%) 0/11 (0%) NA
S1034C 2/39 (5%) 2/60 (3%) 1/47 (2%) 0/11 (0%) NA
N1042D 7/39 (18%) 23/39 (39%) 7/47 (15%) 2/11 (18%) NA

NA=not available.

*

Until July 1994.